english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Antiepileptics and pregnancy: potential long-term effects in children

FEATURED REVIEW Many women who could become pregnant are exposed to antiepileptic drugs. Yet most of the antiepileptic drugs taken by pregnant women expose the unborn child to the risk of malformations, fetotoxic effects and neonatal disorders. What are the long-term effects of the most widely used antieleptics on children exposed in utero, and how do they compare?
Full review (8 pages) available for download by subscribers.
1 January 2020

In the January issue of Prescrire International - Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

FREE DOWNLOAD In the "Reviews" section this month: what is dapagliflozin's harm-benefit balance in type 2 diabetes, in light of the results of a recent randomised, double-blind trial studying the drug's effect on cardiovascular outcomes?
Full text available for free download.
1 January 2020

Persistent psychotic disorders: avoid combining neuroleptics

Combining oral neuroleptics cumulates adverse effects but offers no proven benefits.
1 January 2020

The common cold: echinacea purpurea is no better than placebo

There is no known drug, herbal medicine or other remedy that reduces the intensity or duration of cold symptoms and has a favourable harm-benefit balance.
1 January 2020

Vitamin B6: overdoses leading to neuropathies

With few exceptions, consuming vitamin B6 in addition to food has no medical justification and can lead to overdoses with peripheral neuropathies.
1 January 2020

Updated list of "Drugs to avoid, in the name of better patient care" is published by independent French journal Prescrire

Prescrire "Drugs to avoid" The independent French medical journal Prescrire has published its annual review of "Drugs to avoid", identifying drugs that are clearly more harmful than beneficial. The full report will be published in English in the February 2020 issue of Prescrire International.
1 December 2019

Emicizumab (Hemlibra°) in haemophilia A. A first-choice preventive treatment for patients with factor VIII inhibitors

FEATURED REVIEW Prescrire's editors have rated emicizumab prophylaxis in patients with haemophilia A in whom factor VIII is no longer effective due to the development of factor VIII inhibitors "a real advance". Reduced incidence of bleeding and greater convenience should be weighed against the lack of long-term data, the lack of evaluation in certain clinical situations, and the risk of thrombosis.
Full review (2 pages) available for download by subscribers.
1 December 2019

In the December issue of Prescrire International: pertuzumab (Perjeta°) after surgery for some breast cancers at high risk of recurrence

FREE DOWNLOAD Pertuzumab (Perjeta°) is a monoclonal antibody which has been authorised for use after surgery for some breast cancers. How do Prescrire's editors rate the drug's harm-benefit balance in this situation, in light of the most recent evidence?
Full text available for free download.
1 December 2019

The Mediator° disaster: so much time wasted, so many lives destroyed

1 December 2019

Diclofenac: a habit that needs changing

Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), is routinely used, despite evidence of a greater risk of adverse cardiovascular events when compared with other NSAIDs such as ibuprofen or naproxen, whereas it offers no additional benefit.
1 December 2019

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90